Fluocinonide

Pronunciation: floo-oh-SIN-oh-nide.

Generic name
fluocinonide
Drug class
Topical corticosteroid (potent / high-potency, group III)
Form
Cream, ointment, gel, or solution (0.05% or 0.1%, depending on brand/market)
Route
Topical (skin only)
Legal status
Prescription-only

Availability and supply rules vary by country

Trade names by country: United States · Canada

Australia: · Full directory

What fluocinonide is and how it works

Fluocinonide is a potent prescription topical corticosteroid (a strong anti-inflammatory skin medicine) used to relieve inflammation, redness, and itching from a variety of skin conditions. (1) (2)

Because it is a potent steroid, fluocinonide carries a genuine risk of the body absorbing enough through the skin to affect its own hormone (cortisol) system, especially if used for too long, over too large an area, or under a dressing that traps it against the skin. Always follow your clinician's instructions on how much to use, how often, for how long, and where on the body.

Mechanism of action: how fluocinonide works

Fluocinonide is a synthetic fluorinated corticosteroid with potent anti-inflammatory, antipruritic, and vasoconstrictive activity, acting via glucocorticoid receptor-mediated suppression of inflammatory mediators in the skin; systemic absorption through intact or inflamed skin can activate the same glucocorticoid feedback pathways that regulate the hypothalamic-pituitary-adrenal axis. (1) (2)

What fluocinonide is used for

Corticosteroid-responsive skin conditions

Used to relieve inflammation and itching from skin conditions that respond to corticosteroids, such as eczema, dermatitis, and psoriasis, and (per UK sources) lichen planus and discoid lupus erythematosus of the skin. (1) (2)

Before taking fluocinonide

Do not take / not appropriate for

  • Do not use fluocinonide on rosacea, acne, or perioral dermatitis (a rash around the mouth) -- it can make these conditions worse. (United Kingdom, European Union) (2)
  • Do not use fluocinonide on skin infections (bacterial, tuberculous, syphilitic, fungal, or viral) unless your clinician has specifically directed a combination treatment. (all countries) (2) (1)
  • Do not use fluocinonide for nappy (diaper) rash or on the anogenital area unless specifically directed by your clinician. (United Kingdom, European Union) (2)
  • Do not use more than the amount and duration your clinician or the product label specifies -- exceeding this raises the risk of hormone-system (HPA axis) suppression and skin thinning. (all countries) (1) (2)

Tell your clinician about

  • Any skin infection at or near the area you plan to treat.
  • Whether you have used a potent topical steroid recently or for a long time, especially on the face or under a dressing.
  • Whether you are pregnant, planning pregnancy, or breastfeeding.
  • If the treatment area is large, or if you plan to use a dressing over the treated skin.
  • Any history of skin thinning or previous reactions to topical steroids.
(1) (2)

How to take fluocinonide

  • Apply a thin layer to the affected skin only, as directed by your clinician -- do not use on unaffected skin.
  • Wash your hands after applying, unless the hands are the area being treated.
  • Do not use a bandage, dressing, or wrap over the treated area unless your clinician has specifically told you to -- this increases how much the skin absorbs.
  • Do not use for longer than your clinician recommends, and do not use more than the maximum amount specified for your product -- the US label specifies not longer than 2 consecutive weeks and not more than 60 g (about half of a 120 g tube) per week for the 0.1% cream.
  • Avoid the face, groin, and underarms unless your clinician has specifically directed treatment there.
(1) (2)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5)

Missed dose

If you miss an application, apply it as soon as you remember and continue your regular schedule. Do not apply extra to make up for a missed dose. Contact your clinician or pharmacist if you are unsure.

Overdose

Fluocinonide is applied to the skin, so accidental swallowing or use of a very large amount over a long time should prompt a call to your clinician or a poison-control service, especially if you notice signs of hormone-system disturbance (see serious warnings). (1)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Burning, stinging, or irritation where applied.

What to notice: Burning, stinging, or irritation where applied.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1) (2)

Headache.

What to notice: Headache.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Thinning of the skin, stretch marks (striae), or visible small blood vessels (telangiectasia) with prolonged use.

What to notice: Thinning of the skin, stretch marks (striae), or visible small blood vessels (telangiectasia) with prolonged use.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (2)

Acne-like breakouts or lightening of skin colour at the treated area.

What to notice: Acne-like breakouts or lightening of skin colour at the treated area.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Serious warnings

Signs of hormone-system (HPA axis/adrenal) suppression — serious

Symptoms: Unusual tiredness, weakness, weight loss, low blood pressure, or other signs your clinician may check with a blood or stimulation test.

Action: Contact your clinician if you have used fluocinonide for a long time, over a large area, or under a dressing -- systemic absorption can suppress the body's own cortisol production. Never use for longer than directed or beyond the labelled maximum amount. (1) (2)

Signs of skin thinning or a rebound flare after stopping — high caution

Symptoms: Thin, fragile skin, visible small blood vessels, stretch marks, or -- after stopping prolonged treatment -- intense redness, stinging, and burning of the skin.

Action: Contact your clinician for guidance if you notice these changes, or if your skin condition flares up badly after stopping treatment -- do not restart or increase your steroid use on your own. (2)

Signs of a skin infection developing at the treated site — high caution

Symptoms: New redness, warmth, swelling, pus, or spreading rash at the treated area.

Action: Contact your clinician -- topical steroids can mask or worsen skin infections and treatment may need to be stopped or changed. (1)

Interactions

  • Using fluocinonide together with other topical steroids, or applying it under an occlusive dressing without your clinician's direction, increases how much is absorbed into the body and raises the risk of the warnings above. (1) (2)

Pregnancy, breastfeeding, kidney/liver function, age

Pregnancy

Evidence of safety in human pregnancy is inadequate (UK label); the US label lists it as pregnancy category C, to be used only if the potential benefit justifies the potential risk to the fetus. Discuss with your clinician. (1) (2) (3) (4) (5)

Breastfeeding

It is not known whether topical use produces detectable levels in breast milk. Avoid applying to the breasts before nursing, and minimise the duration and amount used elsewhere on the body while breastfeeding. (1) (2) (3) (4) (5)

Children

Paediatric patients may be more susceptible to systemic absorption and HPA-axis suppression than adults, because of a larger skin-surface-area-to-body-mass ratio. UK guidance limits treatment in children over 1 year to 5 days without occlusion; use in younger children should follow specialist direction. (1) (2) (3) (4) (5)

Elderly

No specific dose adjustment based on age alone is described in the sources reviewed, but older adults with thinner skin may be more prone to skin-related side effects. (1) (2) (3) (4) (5)

Hepatic_impairment

No specific guidance found in the sources reviewed for this dossier. (1) (2) (3) (4) (5)

Renal_impairment

No specific guidance found in the sources reviewed for this dossier. (1) (2) (3) (4) (5)

Source_ids

US-DAILYMED-FLUOCINONIDE-2026,UK-EMC-METOSYN-2026 (1) (2) (3) (4) (5)

Monitoring

Before starting

  • Confirm the diagnosis is a corticosteroid-responsive condition, not an infection
  • Assess treatment area size and any need for a dressing

During treatment

  • Periodic evaluation for HPA-axis suppression if using a large amount, over a large area, for a long time, or under a dressing, per the US label.
  • Watch for skin thinning, stretch marks, or visible blood vessels with prolonged use.
  • Watch for signs of a new skin infection at the treated site.
(1) (2)

Storage

Store at room temperature, away from heat and direct light, out of reach of children, following the exact instructions on your product's label.

Professional information

Clinician-facing context only, sourced from the current US FDA fluocinonide prescribing information and the UK Metosyn SmPC; verify against the current full label for the specific product and formulation before prescribing.

United States

Indication: Corticosteroid-responsive dermatoses

Dose summary: 0.1% cream: thin layer once or twice daily; not beyond 2 consecutive weeks; total dosage not to exceed 60 g/week.

Renal context: No specific renal dosing guidance identified in the sources reviewed. (1)

United Kingdom / European Union

Indication: Corticosteroid-responsive dermatoses

Dose summary: 0.05% cream/ointment: 3-4 times daily initially, reducing to 1-2 times daily on improvement; facial or paediatric treatment limited to 5 days without occlusion.

Renal context: No specific renal dosing guidance identified in the sources reviewed. (2)

Mechanism of action

Hepatic guidance

No specific hepatic dosing guidance identified in the sources reviewed.

Overdose note

Topical overdose is managed by discontinuation and monitoring for signs of HPA-axis suppression; no specific antidote described in the sources reviewed. (1) (2)

Frequently asked questions

Is fluocinonide available in the US, UK, Europe, and Canada?

Yes. It is sold under many brand names -- Vanos/Lidex (United States), Metosyn (United Kingdom), Topsym (Germany), and Lidemol/Lyderm (Canada). A live Medsafe safety alert confirms fluocinonide is not currently an approved medicine in New Zealand. Its availability in Australia could not be confirmed from any live regulator source at the time of writing. (1) (2) (3) (4) (5)

How long can I use fluocinonide for?

Follow your clinician's instructions exactly. The US label for the 0.1% cream advises against use beyond 2 consecutive weeks and against using more than 60 g in a week, because longer or heavier use raises the risk of the body absorbing enough steroid to affect its own hormone system. (1)

Why shouldn't I cover the treated area with a bandage?

Covering (occluding) the treated skin, or using it on very large areas, increases how much of the steroid is absorbed into the body, which raises the risk of hormone-system suppression and skin thinning. Only do this if your clinician has specifically instructed you to. (2) (1)

What is the mechanism of action of fluocinonide?

Fluocinonide is a synthetic fluorinated corticosteroid with potent anti-inflammatory, antipruritic, and vasoconstrictive activity, acting via glucocorticoid receptor-mediated suppression of inflammatory mediators in the skin; systemic absorption through intact or inflamed skin can activate the same glucocorticoid feedback pathways that regulate the hypothalamic-pituitary-adrenal axis. (1) (2)

What is the generic name of Fluocinonide?

The generic name is fluocinonide. (1) (2)

What class of drug is fluocinonide?

Fluocinonide is classed as: Topical corticosteroid (potent / high-potency, group III). (1) (2)

References

  1. FLUOCINONIDE cream USP, 0.1% for topical use -- full prescribing informationU.S. Food and Drug Administration / DailyMed (NIH), full prescribing information · United States · accessed 2026-07-30 · source 1
  2. Metosyn (Fluocinonide 0.05% w/w) Cream/Ointment -- Summary of Product Characteristicselectronic medicines compendium (emc), United Kingdom -- Reig Jofre UK Ltd · United Kingdom · accessed 2026-07-30 · source 2
  3. Topsym (fluocinonide) topical solution/cream/ointment -- German national marketing authorisationBundesinstitut fur Arzneimittel und Medizinprodukte (BfArM), Germany -- national marketing authorisation (representative EU member-state authorisation; fluocinonide is authorised nationally rather than via EMA-centralised procedure) · European Union (Germany) · accessed 2026-07-30 · source 3
  4. LIDEMOL (fluocinonide) and LYDERM (fluocinonide) Product MonographsHealth Canada product monographs, Bausch Health Canada Inc. · Canada · accessed 2026-07-30 · source 4
  5. Medsafe safety alert: Do not use NaturaCoco Moisturising Cream or Dok Apo Moisturiser Soothing CreamMedsafe (New Zealand regulator) -- consumer safety alert · New Zealand · accessed 2026-07-30 · source 5

Brand names by country

Single-ingredient fluocinonide names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries

United States

  • Vanos1 mg/g · bausch health us, llc

Canada

  • LIDEX
  • LYDERM
  • TOPACTIN
  • LIDEMOL EMOLLIENT
  • TIAMOL
  • TOPACTIN EMOLLIENT
View brands in additional countries.

This page provides general reference information about fluocinonide and is not a substitute for advice from the clinician managing your treatment. All dosing, duration, and treatment-area decisions should be made with your prescriber or pharmacist.

Related medicines